An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

STATUS

Recruiting
participants needed

250
sponsor

Genentech, Inc.

Send

Updated on 19 February 2024

See if I qualify

cancer

serum pregnancy test

measurable disease

atezolizumab

solid tumour

solid tumor

anticoagulants

solid neoplasm

Summary

This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.

Details

Condition	Solid Tumors
Age	18years - 100years
Treatment	Atezolizumab, XmAb24306
Clinical Study Identifier	NCT04250155
Sponsor	Genentech, Inc.
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
	Life expectancy >/= 12 weeks
	Adequate hematologic and end-organ function
	For participants receiving therapeutic anticoagulation: stable anticoagulant regimen
	Negative serum pregnancy test for women of childbearing potential
	Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy
	Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
	Availability of representative tumor specimens
Exclusion Criteria
	Pregnant or breastfeeding, or intending to become pregnant during the study
	Significant cardiovascular disease
	Current treatment with medications that prolong the QT interval
	Known clinically significant liver disease
	Poorly controlled Type 2 diabetes mellitus
	Symptomatic, untreated, or actively progressing CNS metastases
	History of leptomeningeal disease
	History of malignancy other than disease under study within 3 years prior to screening
	Active or history of autoimmune disease or immune deficiency
	Active tuberculosis, hepatitis B, hepatitis C, or known/suspected Epstein Barr virus infection
	Positive for HIV infection
	Prior allogeneic stem cell or solid organ transplantation

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors